Pharmacokinetic, Pharmacodynamic Profiles and Safety After Oral Administration of Ivabradine in Male Healthy Korean Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

September 30, 2007

Study Completion Date

November 30, 2007

Conditions
Healthy Individual
Interventions
DRUG

Ivabradine and placebo

Single and repeated oral administrations of 3 doses of ivabradine (2.5, 5, and 10 mg). Subjects were given a single administration of ivabradine during Period 1 (P1), following a 3-day washout, they were given repeated administrations twice daily for 4.5 days during Period 2 (P2).

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Institut de Recherches Internationales Servier

OTHER

lead

Asan Medical Center

OTHER